Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Coronavirus update: A summit in Geneva, WuXi hunts antibodies and J&J partners on a vaccine search
6 years ago
R&D
Coronavirus
Corey Goodman marshals $105M mega-round for his CD47 upstart, looking to break new ground in PhII
6 years ago
Financing
Startups
Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
6 years ago
R&D
Pharma
New Sanofi chief Paul Hudson takes the ax to his executive committee, chopping 4 key players
6 years ago
R&D
Lilly, Novo Nordisk fight insulin biosimilars with tweaks to FDA draft guidance
6 years ago
Pharma
FDA+
Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease ...
6 years ago
R&D
FDA+
Ligand buys its way into partnership with Roche, CF Foundation — plus some ion channel tech once owned by Pfizer
6 years ago
Deals
Bayer hands over a big drug R&D operation to CRO amid an ongoing restructuring effort
6 years ago
Deals
R&D
A Chinese company is already mass producing Gilead's experimental coronavirus drug
6 years ago
China
Coronavirus
The Wuhan coronavirus has an official name: COVID-19; Revolution Medicines upsizes IPO terms
6 years ago
News Briefing
Coronavirus
Agios' Lewis Cantley returns with a new company and, he claims, a major oncological discovery
6 years ago
R&D
Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug
6 years ago
Deals
R&D
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
6 years ago
FDA+
Upstart cancer biotech recruits a top Pfizer oncology researcher as CSO — could an IPO be far behind?
6 years ago
R&D
Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish ...
6 years ago
R&D
Moderna eyes $500M secondary offering on upbeat coronavirus vaccine update — almost ready for the clinic
6 years ago
Deals
Coronavirus
Merck walks away from KalVista, who turns their sights on HAE
6 years ago
Deals
Trump’s 2021 budget request seeks modest funding increase for FDA
6 years ago
FDA+
FDA slaps a hold on LogicBio and its gene editing plans — shares tumble
6 years ago
Cell/Gene Tx
FDA+
With blockbuster dreams, Exelixis is looking for some redemption for cabo in prostate cancer. It won’t be easy
6 years ago
R&D
Pharma
Vivek Ramaswamy's Arbutus kills another program over safety, stock takes another hit
6 years ago
R&D
Are priority review voucher programs stimulating drug development? The data suggest not really, finds GAO report
6 years ago
R&D
FDA+
Eye drop developer Oculis showcases positive PhII data; Aquestive hunts for another FDA OK
6 years ago
News Briefing
Science team designs a new CAR they say may work much better than BCMAs in fighting multiple myeloma
6 years ago
R&D
First page
Previous page
858
859
860
861
862
863
864
Next page
Last page